X-Nico

unusual facts about Phospholipase A2|phospholipase A2phospholipase A2.




Angel Ortiz

He became involved in a project financed mostly by Menarini Pharmaceuticals, aimed at the rationalization of the biochemical activity of a number of phospholipase A2 (PLA2) enzymes from different sources and, ultimately, at the design of novel inhibitors of human synovial fluid PLA2 tagged as anti-inflammatory agents.

Calliophis bivirgatus

Fraction S2 contains two phospholipases A2 — PLA2 I and PLA2 II; fraction S3 contains four cytotoxin homologues — maticotoxins A, C, D1 and D2; and fractions S4 and S5 contain a large amount (about 1 mg/specimen) of adenosine with smaller amounts of inosine and guanosine.

Equatorial spitting cobra

The venom of the Equatorial spitting cobra exhibited the common characteristic enzymatic activities of Asiatic spitting cobra venoms: low protease, phosphodiesterase, alkaline phosphomonoesterase and L-amino-acid oxidase activities, moderately high acetylcholinesterase and hyaluronidase activities and high Phospholipase A

An enzyme that displays both phospholipase A1 and phospholipase A2 activities is called a Phospholipase B (see main article on phospholipases).

Selective glucocorticoid receptor agonist

These target genes encode proteins such as cyclooxygenase, NO synthase, phospholipase A2, tumor necrosis factor, transforming growth factor beta, ICAM-1, and a number of other pro-inflammatory proteins.

Varespladib methyl

Varespladib methyl (also known as A-002, formerly LY333013 and S-3013) is a secretory phospholipase A2 (sPLA2) inhibitor formerly under development by Anthera Pharmaceuticals as a treatment for acute coronary syndrome (ACS).


see also